NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD
1.5
+0.03 (+2.04%)
The current stock price of NLSP is 1.5 USD. In the past month the price decreased by -2.6%. In the past year, price decreased by -72.57%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 66.13 | 815.02B | ||
JNJ | JOHNSON & JOHNSON | 15.42 | 373.36B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.1 | 278.02B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14 | 219.57B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.63B | ||
MRK | MERCK & CO. INC. | 10.25 | 200.91B | ||
SNY | SANOFI-ADR | 13.69 | 131.07B | ||
PFE | PFIZER INC | 7.32 | 129.20B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.63 | 99.07B | ||
GSK | GSK PLC-SPON ADR | 8.62 | 75.99B | ||
ZTS | ZOETIS INC | 25.73 | 67.93B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.15 | 47.56B |
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 3 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
NLS PHARMACEUTICS LTD
The Circle 6
Zurich ZUERICH CH-6370 CH
CEO: Alexander Zwyer
Employees: 7
Company Website: https://nlspharma.com/
Investor Relations: http://nlspharma.com/investors/sec-filings/
Phone: 41445122150
The current stock price of NLSP is 1.5 USD. The price increased by 2.04% in the last trading session.
The exchange symbol of NLS PHARMACEUTICS LTD is NLSP and it is listed on the Nasdaq exchange.
NLSP stock is listed on the Nasdaq exchange.
NLS PHARMACEUTICS LTD (NLSP) has a market capitalization of 2.97M USD. This makes NLSP a Nano Cap stock.
NLS PHARMACEUTICS LTD (NLSP) currently has 7 employees.
NLS PHARMACEUTICS LTD (NLSP) has a support level at 1.4 and a resistance level at 1.51. Check the full technical report for a detailed analysis of NLSP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NLSP does not pay a dividend.
NLS PHARMACEUTICS LTD (NLSP) will report earnings on 2022-12-13, before the market open.
NLS PHARMACEUTICS LTD (NLSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.72).
The outstanding short interest for NLS PHARMACEUTICS LTD (NLSP) is 3.16% of its float. Check the ownership tab for more information on the NLSP short interest.
ChartMill assigns a fundamental rating of 1 / 10 to NLSP. NLSP may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NLSP reported a non-GAAP Earnings per Share(EPS) of -6.72. The EPS increased by 19.12% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -552.58% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to NLSP. The Buy consensus is the average rating of analysts ratings from 6 analysts.